- Home
- CISS vs VRAX Comparison
CISS vs VRAX Comparison
Compare CISS & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | VRAX |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | Greece | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 2.1M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CISS | VRAX |
|---|---|---|
| Price | $1.28 | $2.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 403.8K | 57.0K |
| Earning Date | 05-19-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.10 |
| 52 Week High | $6.06 | $13.19 |
Technical Indicators
Market Signals| Indicator | CISS | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 49.22 | 44.90 |
| Support Level | $0.76 | $2.54 |
| Resistance Level | $1.84 | $2.92 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 30.51 | 27.64 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.